At a glance
What is it—and why does it matter?
An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
How does it work?
Target, response, and disposition.
Mechanism
A nanoparticle delivery approach is described in which polymyxin B is encapsulated/loaded into silver nanoparticles capped/stabilized with polyvinylpyrrolidone, aiming to deliver antimicrobial activity via this carrier system.
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This study reports the development of PMB-loaded silver nanoparticles (AgNPs) stabilized with polyvinylpyrrolidone (PVP) as a novel antimicrobial delivery system.”
Polymyxin B-loaded PVP-capped silver nanoparticles: A potent approach against multidrug-resistant bacteria. · Abstract
pubmed:42287940:48036bfe1d3b:48036bfe1d3b
Pharmacokinetics
Physicochemical characterization of the optimized polymyxin B nanoparticle formulation (PMB-AgNPs-0.5) reports nanoscale size with a stated polydispersity, substantial encapsulation efficiency, and a mildly positive zeta potential, which are key parameters for nanoparticle performance.
- Reported result
- 95.9 ± 0.28 nm; 0.202 ± 0.06; 70.79 ± 2.5%; +2.82 mV
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The optimized formulation (PMB-AgNPs-0.5) exhibited an average size of 95.9 ± 0.28 nm, a polydispersity index of 0.202 ± 0.06, encapsulation efficiency of 70.79 ± 2.5%, and a zeta potential of +2.82 mV.”
Polymyxin B-loaded PVP-capped silver nanoparticles: A potent approach against multidrug-resistant bacteria. · Abstract
pubmed:42287940:48036bfe1d3b:48036bfe1d3b
What has been studied?
What the evidence says.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, effect, identity, interaction, regulatory, safety
- 56 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (35), assurance_score_below_0.72 (20), current_regulatory_source_required (13), extraction_ambiguity (49), extraction_confidence_not_high (6), high_risk_requires_regulatory_or_two_independent_sources (20), no_direct_support (54)
- A source-backed introductory overview is not yet available.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Polymyxin B-loaded PVP-capped silver nanoparticles: A potent approach against multidrug-resistant bacteria. ↗
pubmed · published 2026-11-01 · retrieved 2026-08-29T08:37:13Z
Publication history and provenance
Version 1 · Automated assessment · 2026-08-29T08:37:13Z
0344843d26a389739a4eed99aa1ae64e52ac4cb188e0a3fbe36bff9995b49e77